153 related articles for article (PubMed ID: 34954822)
1. Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment.
Boggio E; Gigliotti CL; Moia R; Scotta A; Crespi I; Boggione P; De Paoli L; Deambrogi C; Garzaro M; Vidali M; Chiocchetti A; Stoppa I; Rolla R; Dianzani C; Monge C; Clemente N; Gaidano G; Dianzani U
Br J Haematol; 2022 Mar; 196(6):1369-1380. PubMed ID: 34954822
[TBL] [Abstract][Full Text] [Related]
2. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
Yan X; Gu Y; Wang C; Sun S; Wang X; Tian J; Wang M; Ji X; Duan X; Gao H; Fang Q; Dong W; Zhang X; Xue Q
Clin Immunol; 2019 Oct; 207():68-78. PubMed ID: 31374257
[TBL] [Abstract][Full Text] [Related]
3. Deep Flow Cytometry Unveils Distinct Immune Cell Subsets in Inducible T Cell Co-Stimulator Ligand (ICOSL)- and ICOS-Knockout Mice during Experimental Autoimmune Encephalomyelitis.
Raineri D; Abreu H; Vilardo B; Kustrimovic N; Venegoni C; Cappellano G; Chiocchetti A
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473756
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients.
Zhan XK; Liu XK; Zhang S; Chen H
Animal Model Exp Med; 2023 Oct; 6(5):464-473. PubMed ID: 37850501
[TBL] [Abstract][Full Text] [Related]
5. Role of the co-stimulatory molecule inducible T-cell co-stimulator ligand (ICOSL) in the progression of experimental metabolic dysfunction-associated steatohepatitis.
Provera A; Ramavath NN; Gadipudi LL; Gigliotti CL; Boggio E; Vecchio C; Stoppa I; Rolla R; Boldorini R; Pirisi M; Smirne C; Albano E; Dianzani U; Sutti S
Front Immunol; 2023; 14():1290391. PubMed ID: 38077334
[TBL] [Abstract][Full Text] [Related]
6. ICOS-Fc as innovative immunomodulatory approach to counteract inflammation and organ injury in sepsis.
Alves GF; Stoppa I; Aimaretti E; Monge C; Mastrocola R; Porchietto E; Einaudi G; Collotta D; Bertocchi I; Boggio E; Gigliotti CL; Clemente N; Aragno M; Fernandes D; Cifani C; Thiemermann C; Dianzani C; Dianzani U; Collino M
Front Immunol; 2022; 13():992614. PubMed ID: 36119089
[TBL] [Abstract][Full Text] [Related]
7. ICOS/ICOSL upregulation mediates inflammatory response and endothelial dysfunction in type 2 diabetes mellitus.
Zhang HY; Ruan LB; Li Y; Yang TR; Liu WJ; Jiang YX; Li TR; Quan J; Xuan W
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8898-8908. PubMed ID: 30575933
[TBL] [Abstract][Full Text] [Related]
8. Inducible costimulator (ICOS) and ICOS ligand signaling has pivotal roles in skin wound healing via cytokine production.
Maeda S; Fujimoto M; Matsushita T; Hamaguchi Y; Takehara K; Hasegawa M
Am J Pathol; 2011 Nov; 179(5):2360-9. PubMed ID: 21925472
[TBL] [Abstract][Full Text] [Related]
9. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
Solinas C; Gu-Trantien C; Willard-Gallo K
ESMO Open; 2020 Jan; 5(1):. PubMed ID: 32516116
[TBL] [Abstract][Full Text] [Related]
10. Inducible T-Cell Costimulator Mediates Lymphocyte/Macrophage Interactions During Liver Repair.
Ramavath NN; Gadipudi LL; Provera A; Gigliotti LC; Boggio E; Bozzola C; Albano E; Dianzani U; Sutti S
Front Immunol; 2021; 12():786680. PubMed ID: 34925367
[TBL] [Abstract][Full Text] [Related]
11. ADAM10-Mediated ICOS Ligand Shedding on B Cells Is Necessary for Proper T Cell ICOS Regulation and T Follicular Helper Responses.
Lownik JC; Luker AJ; Damle SR; Cooley LF; El Sayed R; Hutloff A; Pitzalis C; Martin RK; El Shikh MEM; Conrad DH
J Immunol; 2017 Oct; 199(7):2305-2315. PubMed ID: 28814605
[TBL] [Abstract][Full Text] [Related]
12. Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis.
Hasegawa M; Fujimoto M; Matsushita T; Hamaguchi Y; Takehara K
Rheumatology (Oxford); 2013 Feb; 52(2):242-51. PubMed ID: 23024058
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stem cells regulate type 2 innate lymphoid cells via regulatory T cells through ICOS-ICOSL interaction.
Fan X; Xu ZB; Li CL; Zhang HY; Peng YQ; He BX; Liu XQ; Chen DH; Chen D; Akdis CA; Fu QL
Stem Cells; 2021 Jul; 39(7):975-987. PubMed ID: 33662168
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of ICOS ligand by interaction with ICOS functions as a regulatory mechanism for immune responses.
Watanabe M; Takagi Y; Kotani M; Hara Y; Inamine A; Hayashi K; Ogawa S; Takeda K; Tanabe K; Abe R
J Immunol; 2008 Apr; 180(8):5222-34. PubMed ID: 18390703
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel monoclonal antibody to human inducible co-stimulator ligand (ICOSL): Biological characteristics and application for enzyme-linked immunosorbent assay.
Hu X; Wu J; An J; Hu Y; Shen Y; Liu C; Zhang X
Int Immunopharmacol; 2016 Jul; 36():151-157. PubMed ID: 27138044
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus restricts ICOSL expression on antigen-presenting cells disabling T cell co-stimulation and contributing to immune evasion.
Angulo G; Zeleznjak J; Martínez-Vicente P; Puñet-Ortiz J; Hengel H; Messerle M; Oxenius A; Jonjic S; Krmpotić A; Engel P; Angulo A
Elife; 2021 Jan; 10():. PubMed ID: 33459589
[TBL] [Abstract][Full Text] [Related]
17. Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells.
Han Y; Dong Y; Yang Q; Xu W; Jiang S; Yu Z; Yu K; Zhang S
Front Immunol; 2018; 9():2227. PubMed ID: 30319662
[TBL] [Abstract][Full Text] [Related]
18. MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells.
Zheng Z; Xu PP; Wang L; Zhao HJ; Weng XQ; Zhong HJ; Qu B; Xiong J; Zhao Y; Wang XF; Janin A; Zhao WL
J Exp Clin Cancer Res; 2017 Jun; 36(1):82. PubMed ID: 28637496
[TBL] [Abstract][Full Text] [Related]
19. ICOS regulates the generation and function of human CD4+ Treg in a CTLA-4 dependent manner.
Zheng J; Chan PL; Liu Y; Qin G; Xiang Z; Lam KT; Lewis DB; Lau YL; Tu W
PLoS One; 2013; 8(12):e82203. PubMed ID: 24312642
[TBL] [Abstract][Full Text] [Related]
20. Immunofibroblasts regulate LTα3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction.
Nayar S; Pontarini E; Campos J; Berardicurti O; Smith CG; Asam S; Gardner DH; Colafrancesco S; Lucchesi D; Coleby R; Chung MM; Iannizzotto V; Hunter K; Bowman SJ; Carlesso G; Herbst R; McGettrick HM; Browning J; Buckley CD; Fisher BA; Bombardieri M; Barone F
Commun Biol; 2022 May; 5(1):413. PubMed ID: 35508704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
